Merck & Co.’s Covid-19 antivirals are getting a new lease of life in post-pandemic China, as cat owners seize on them as ...

GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...

Shares of Merck & Co. Inc. MRK slipped 0.03% to $99.14 Friday, on what proved to be an all-around great trading session for ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...

The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...

Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.

Drugmakers plan to raise US prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, Bristol ...

Shares of Merck & Co. Inc. MRK slumped 0.31% to $99.17 Thursday, on what proved to be an all-around dismal trading session ...

Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair ...

BMO Capital Markets has recently reduced Merck & Co Inc (MRK) stock to Market Perform rating, as announced on December 20, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had ...

Get insights on top Dow Dogs like Verizon and Merck, with potential net gains forecasted by analysts. Click for the January ...